HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
Rhea-AI Summary
HOPE Therapeutics (Nasdaq: NRXP) opened a Palm Beach, FL clinic on March 9, 2026, offering one‑day interventional psychiatry treatments for depression and PTSD that combine ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen, and physician‑led psychotherapy.
Peer‑reviewed publications cited an 87% clinical response rate for a short‑term TMS plus neuroplastic medication protocol; pilot programs with added hyperbaric oxygen reported a 90% return to full function rate. HOPE cites a nationwide partnership with neurocare AG and is now accepting patients by phone.
Positive
- Opened Palm Beach clinic on March 9, 2026
- 87% published clinical response for short‑term TMS plus neuroplastic drugs
- Pilot programs reported 90% return to full function with hyperbaric oxygen
- Nationwide partnership with neurocare AG to bring non‑invasive treatments
Negative
- Published response rates may not predict outcomes for individual patients
- Hyperbaric oxygen results reported as pilot data, not definitive randomized trials
News Market Reaction – NRXP
In the Mar 9 session, NRXP gained 1.76%, reflecting a mild positive market reaction. Argus tracked a peak move of +14.2% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 05 | Clinic network partnership | Positive | -8.0% | Nationwide neuroplastic therapy clinic network with neurocare AG for depression and PTSD. |
| Apr 18 | Public offering priced | Negative | -27.8% | Pricing of $2.0M underwritten public offering of common stock. |
| Apr 17 | Public offering proposed | Negative | -27.8% | Announcement of proposed underwritten public offering of common stock. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Offering-related announcements have often coincided with negative price moves, including a decline after a positive clinic-partnership expansion, indicating sensitivity to financing and commercialization structures.
Over recent offering-tagged events, NRx used news to advance both financing and commercialization. On Jan 5, 2026, it announced a nationwide clinic network partnership with neurocare AG, but the stock fell 8.02%. In April 2024, both a proposed and a priced underwritten public offering each saw -27.75% reactions, underscoring investor concern around dilution. Today’s HOPE Therapeutics clinic opening fits the same neuroplastic-therapy rollout theme but contrasts with the more financing-centric 2024 offerings.
Key Terms
transcranial magnetic stimulation medical
hyperbaric oxygen medical
post-traumatic stress disorder medical
Alzheimer’s disease medical
Traumatic Brain Injury medical
ketamine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Published results have shown
87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications. - Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities.
- Now accepting patients, call 1-833-4HOPETMS
WEST PALM BEACH, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced the opening of its Palm Beach, FL clinic location dedicated to the treatment of Depression and PTSD with an interventional psychiatry approach that includes ketamine1 and other neuroplastic drugs, transcranial magnetic stimulation (TMS), and hyperbaric oxygen, combined with physician-led psychotherapy. This clinic location is the most recent addition to HOPE’s growing network of clinics.
Peer-reviewed scientific publications have shown an
“Prior to the advent of modern neuroplastic therapies for depression, PTSD, and related conditions, patients were primarily treated with traditional antidepressants which are now understood to work only
The clinical results that have been published in the medical literature are based on a broad array of patients and may or may not reflect the results achieved by any individual patient.
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com), a subsidiary of NRx Pharmaceuticals, is a Healthcare delivery company that is building a best-in-class network of interventional psychiatry clinics to offer ketamine and other neuroplastic medications, transcranial magnetics stimulation (TMS), Hyperbaric Oxygen Therapy, and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy. HOPE is the first network in Florida to offer the AMPA One Day (ONE-D) treatment that combines TMS, physician-prescribed D-cycloserine, and lisdexamfetamine to achieve rapid remission from treatment resistant depression.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com
__________________
1 Ketamine is currently FDA-approved as an anesthetic but is not indicated for use in treating depression, although it is used by practicing physicians for that purpose and is the subject of numerous scientific publications. It has been identified by the US Department of Veterans Affairs as a drug that may be "medically necessary" for "Treatment Resistant Depression" and for "Depression with severe suicidal ideation. The appropriateness of ketamine for any particular patient is a doctor/patient decision that can only be made within the scope of clinical practice of medicine.
